About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« USPTO News: EFS-Web 1.4 Enhancements Coming Soon | Main | Conference & CLE Calendar »

August 01, 2008

Teva and Dr. Reddy's Settle Coreg® Suit

    By Sherri Oslick --

Dr_reddys Earlier this week the litigation between Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Inc. over generic Coreg® was dismissed without costs and without prejudice based on a settlement between the parties.

Teva_1 As we reported previously, the suit was originally filed in the District Court of New Jersey on June 21, 2007 against Dr. Reddy's for infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004), 6,710,184 ("Crystalline Solids of Carvedilol and Processes for Their Preparation," issued March 23, 2004), 7,056,942 ("Carvedilol," issued June 6, 2006), and 7,126,008 (same title, issued October 24, 2006) based on defendants' filing of an ANDA to manufacture and sell a generic version of GSK's Coreg® (carvedilol, used to treat congestive heart failure and high blood pressure).  Dr. Reddy's ANDA was approved by the FDA in September, 2007, at the end of GSK's pediatric exclusivity period.

Posted at 10:27 PM in Patent Litigation |

Comments

The comments to this entry are closed.

April 2025

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Categories

Archives

More...